Assessing the impact of COVID-19 on sleep and cognitive health
Predictors of Post-COVID Clinical and Cognitive Consequences
This study is trying to see how COVID-19 affects sleep and thinking in people who have recovered from the virus, to better understand long-term health issues they might face.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | VA Office of Research and Development Federal |
| Locations | 1 site (Detroit, Michigan) |
| Trial ID | NCT06291870 on ClinicalTrials.gov |
What this trial studies
This observational study aims to systematically evaluate the relationship between sleep disturbances, obstructive sleep apnea, and post-acute sequelae of SARS-CoV-2 infection (PASC) in individuals who have recovered from COVID-19. It will collect data on sleep quality, cognitive function, and fatigue symptoms to understand how these factors may influence long-term health outcomes. The study will also explore the role of inflammatory biomarkers during acute COVID-19 infection in predicting the severity and duration of PASC. This pilot study serves as a foundation for future research on the connections between long-COVID and sleep-related issues.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 18 and older with a prior diagnosis of COVID-19, particularly those with obstructive sleep apnea.
Not a fit: Patients who are unable to provide consent, exhibit active suicidal symptoms, or are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for post-COVID conditions, enhancing quality of life for affected patients.
How similar studies have performed: While this study explores novel connections between COVID-19 and sleep disturbances, similar studies have indicated the importance of sleep quality in overall health outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All individuals 18 years or older, with prior history of COVID-19 infection diagnosis * Both genders including all racial and ethnic groups * Patients with OSA (apnea hypopnea index of 5/hour on polysomnography) with history of COVID-19 infection will be eligible with prior history of COVID-19 infection and without COVID-19 for Aim 2 Exclusion Criteria: * Inability to give consent * Active suicidal symptoms * Children of all ages * Pregnant women
Where this trial is running
Detroit, Michigan
- John D. Dingell VA Medical Center, Detroit, MI — Detroit, Michigan, United States (Recruiting)
Study contacts
- Principal investigator: Susmita Chowdhuri, MD MS — John D. Dingell VA Medical Center, Detroit, MI
- Study coordinator: Ruchi Rastogi, MS
- Email: ruchi.rastogi@va.gov
- Phone: (313) 576-4464
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.